Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-384 in Mild-to-Moderate Alzheimer's Disease
2009-017801-12Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABT-384 in Alzheimer's disease (AD) (4 arms), sponsored by Abbott Laboratories. Primary endpoint: ADAS-cog. Started Mar 2010; status: terminated.
02
Drugs
ABT-384
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-017801-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017801-12.